Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Operating Leases (2019 - 2025)

Guided Therapeutics' Operating Leases history spans 7 years, with the latest figure at $104000.0 for Q2 2025.

  • For Q2 2025, Operating Leases changed 0.0% year-over-year to $104000.0; the TTM value through Jun 2025 reached $104000.0, changed 0.0%, while the annual FY2024 figure was $155000.0, 0.0% changed from the prior year.
  • Operating Leases for Q2 2025 was $104000.0 at Guided Therapeutics, up from $20000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $418000.0 in Q1 2021 and bottomed at $20000.0 in Q1 2025.
  • The 5-year median for Operating Leases is $256500.0 (2022), against an average of $226277.8.
  • The largest annual shift saw Operating Leases soared 4080.0% in 2021 before it tumbled 84.62% in 2025.
  • A 5-year view of Operating Leases shows it stood at $325000.0 in 2021, then decreased by 24.31% to $246000.0 in 2022, then tumbled by 36.99% to $155000.0 in 2023, then changed by 0.0% to $155000.0 in 2024, then tumbled by 32.9% to $104000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Operating Leases are $104000.0 (Q2 2025), $20000.0 (Q1 2025), and $155000.0 (Q4 2024).